title: [Use of 18F FDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative ¹³¹I scan].
abstract: OBJECTIVE
  To evaluate the utility of (18F)FDG-PET for patients diagnosed of differentiated thyroid carcinoma who present risk of disease and invaluable levels of thyroglobulin (Tg) by the presence of antibodies antithyroglobulin (AbTg).
  
  
  METHODS
  Retrospective study of 7 women of 40 years old and histological diagnosis of differentiated thyroid cancer (7 papillary tumours) that were sent to our department for the accomplishment of(18F)FDG-PET study because of suspicion of disease, due to ¹³¹I negative and high levels of AbTg, between the year 2002 and 2007. 11 PET scans were obtained after the intravenous injection of 370-434 MBq of (18F)FDG in normoglycemia conditions and previous administration of muscle relaxant, hydration and diuretic. The results of (18F)FDG-PET scans were confirmed by pathologic examination or clinical outcome and radiographic examination for more than 24 months.
  
  
  RESULTS
  The prevalence of recurrence in our population was 57.14%. All patients presented levels of Tg lower than 3 ng/dl and AbTg superior to 200 UI/ml. Three patients had precedent thyroiditis. Out of 11 scans performed 3 of them were negative and 8 cases were found positive. It ruled out the existence of disease in three patients and localized the presence of recurrence in 4 patients.
  
  
  CONCLUSIONS
  (18F)FDG-PET CONCLUSION: 18F-FDG-PET is a useful diagnostic tool for the detection of recurrence as well as to rule out the existence of disease with a high accuracy, in patients with differentiated thyroid carcinoma with ¹³¹I whole body scan negative but with pathological elevation of antithyroglobulin antibodies.
authors.affiliation: Unidad de Gestión Diagnóstica de Medicina Nuclear, Hospital Universitario Virgen del Rocío, Seville, Spain. salomesanzv@gmail.com
authors.forename: S
authors.initials: S
authors.lastname: Sanz Viedma
authors.forename: I
authors.initials: I
authors.lastname: Borrego Dorado
authors.forename: J R
authors.initials: JR
authors.lastname: Rodríguez Rodríguez
authors.forename: E
authors.initials: E
authors.lastname: Navarro González
authors.forename: R
authors.initials: R
authors.lastname: Vázquez Albertino
authors.forename: R
authors.initials: R
authors.lastname: Fernández López
authors.forename: A
authors.initials: A
authors.lastname: Agudo Martínez
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000097:blood*; D001324:Autoantigens / Q000097:blood / Q000276:immunology; D014408:Biomarkers, Tumor / Q000097:blood; D002291:Carcinoma, Papillary / Q000097:blood / Q000000981:diagnostic imaging* / Q000556:secondary* / Q000601:surgery; D005260:Female; D005462:Fluorine Radioisotopes / Q000008:administration & dosage; D019788:Fluorodeoxyglucose F18 / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007457:Iodine Radioisotopes; D008175:Lung Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000556:secondary*; D008207:Lymphatic Metastasis / Q000000981:diagnostic imaging*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000000981:diagnostic imaging*; D049268:Positron-Emission Tomography; D015995:Prevalence; D019275:Radiopharmaceuticals / Q000008:administration & dosage; D012189:Retrospective Studies; D013954:Thyroglobulin / Q000097:blood / Q000276:immunology; D013964:Thyroid Neoplasms / Q000097:blood / Q000000981:diagnostic imaging* / Q000276:immunology / Q000601:surgery; D013965:Thyroidectomy; D013967:Thyroiditis, Autoimmune / Q000097:blood / Q000000981:diagnostic imaging / Q000276:immunology; D055815:Young Adult
chemical_list: D001323:Autoantibodies; D001324:Autoantigens; D014408:Biomarkers, Tumor; D005462:Fluorine Radioisotopes; D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; C006606:anti-thyroglobulin; D019788:Fluorodeoxyglucose F18; D013954:Thyroglobulin